John H. Rex, MD

Dr. John H. Rex is the Chief Medical Officer of F2G. He is a distinguished research scientist and a key opinion leader in the field of infectious disease therapy, specializing in antifungal agents. Prior to joining F2G, John held the positions of Senior Vice President and Head of Infection, Global Medicines Development, at AstraZeneca until 2016. Prior to joining AstraZeneca in 2003, he was a Professor of Medicine at the University of Texas Medical School at Houston. John has been the Industry Representative on the US FDA Anti-Infective Drug Advisory Committee (2007-2011), has served as Chair of the Consensus Committee on Microbiology for the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS), is a member of the Wellcome Trust Seeding Drug Discovery Committee, was formerly an Editor of Antimicrobial Agents and Chemotherapy, and currently serves on several editorial boards.

John holds a BA in biochemistry from Rice University and an MD from the Baylor College of Medicine in Texas. He has served as a Non-Executive Director of F2G since 2012 and is an Operating Partner at Advent Life Sciences.